FCHI8,141.92-0.19%
GDAXI24,083.53-0.19%
DJI49,167.79-0.13%
XLE56.840.12%
STOXX50E5,860.32-0.39%
XLF51.820.02%
FTSE10,321.09-0.56%
IXIC24,887.100.20%
RUT2,788.190.04%
GSPC7,173.910.12%
Temp30.3°C
UV1.5
Feels35.7°C
Humidity59%
Wind10.8 km/h
Air QualityAQI 1
Cloud Cover25%
Rain0%
Sunrise06:00 AM
Sunset06:47 PM
Time5:15 PM
TLPPFPNKHealthcare

Telix Pharmaceuticals Limited

$9.75
-0.70 (-6.70%)

News

(4)

April 2026

2 weeks ago6-K

FDA Accepts Telix's Brain Cancer Imaging Drug for Review

TLPPFTelix Pharmaceuticals Ltd

# 🧾 What This Document Is This is a **6-K filing**, which is how foreign companies listed on U.S. exchanges (like Telix, which is Australian) report major news to the SEC. This specific report announces a major regulatory milestone for one of their key drug candidates. # 🏢 What The Company Does �

Read summaryView on SEC EDGAR
2 weeks ago6-K

Telix Pharmaceuticals Ltd — 6-K Filing

TLPPFTelix Pharmaceuticals Ltd

# 🧾 What This Document Is This is a **6-K form**, which is a report foreign companies like Telix (an Australian company listed on the US Nasdaq) file with the SEC to share major news with American investors. Think of it as a formal, required announcement to the US market. 👉 **In simple terms:** T

Read summaryView on SEC EDGAR
2 weeks ago6-K

Telix Pharmaceuticals Ltd — 6-K Filing

TLPPFTelix Pharmaceuticals Ltd

# 🧾 What This Document Is This is a **Q1 2026 Quarterly Business Update** from Telix Pharmaceuticals. Think of it as a progress report for investors, showing how the company performed in the first three months of the year and what major milestones it hit. It's not an official earnings report yet (t

Read summaryView on SEC EDGAR
3 weeks ago6-K

Telix Pharmaceuticals Ltd — 6-K Filing

TLPPFTelix Pharmaceuticals Ltd

# 🧾 What This Document Is This is a **Form 6-K**, a report foreign companies like Australia's Telix Pharmaceuticals file with the U.S. SEC to keep American investors informed of major news. This specific report is an **ASX announcement** (the Australian stock exchange) detailing two key leadership

Read summaryView on SEC EDGAR